Fact check: What are the common inactive ingredients in ivermectin tablets for humans?

1. Why the ingredient lists converge — the common inactive agents manufacturers name

The available package inserts and product documents repeatedly identify microcrystalline cellulose, pregelatinized starch, and magnesium stearate as central inactive components in ivermectin tablets, reflecting their widespread use as fillers, binders, and lubricants in solid oral dosage forms ^[1]. Several documents expand this core list to include croscarmellose sodium and colloidal silicon dioxide, which function as disintegrants and glidants respectively, and are present in at least one modern insert in the dataset ^[1]. These commonalities indicate a consensus across the sampled prescribing information that the manufacturing platform for oral ivermectin uses similar excipient classes, meaning the active formulation approach is broadly consistent in the referenced sources ^[1].

2. Where the product labels differ — brand-specific or older variations matter

The sources show notable but limited divergence where certain brands, particularly Stromectol/STROMECTOL, include ingredients not listed in other package inserts, such as butylated hydroxyanisole (BHA) and citric acid alongside the common excipients ^{[2] [3] [4]}. These differences could reflect brand-specific stabilizers, antioxidant choices, or regional formulation practices, and one source explicitly notes that Stromectol’s inactive ingredient list is “slightly different” from other ivermectin tablets ^[4]. The documents thus present a picture where formulation variability is present but limited, and differences are mostly in secondary excipients rather than the primary binder and lubricant components ^{[2] [4]}.

3. Dates and provenance — what the timeline of the documents reveals

The dataset contains both recent and older entries: package inserts labeled with 2025 dates appear alongside Stromectol/STROMECTOL documents from 2021 and 2006, showing that the same core inactive ingredients persist across time even as minor excipients vary ^{[1] [2] [4]}. The 2025-labeled prescribing information reiterates the microcrystalline cellulose–pre-gelatinized starch–magnesium stearate triad, while earlier Stromectol documents introduce BHA and citric acid; this suggests longstanding formulation continuity for primary excipients with occasional historical or brand-driven additions ^{[1] [2] [4]}. The consistency across dates strengthens confidence that the listed inactive ingredients are representative of marketed human ivermectin tablets in these sources ^[1].

4. What these ingredient differences mean for patients — allergy, intolerance, and regulatory context

From the provided materials, the practical implication is that people with sensitivities to specific excipients should consult the particular product’s prescribing information because brands like Stromectol may include antioxidants (BHA) or citric acid that other generic ivermectin tablets do not list ^{[2] [3]}. The dataset does not provide adverse-event data or regulatory commentary, so the documents’ value is primarily informational for screening allergies and drug interactions rather than evidentiary about safety incidents; consequently, clinicians and patients are advised to match the exact tablet label to individual tolerance and allergy histories when choosing or dispensing the product ^{[1] [3] [4]}.

5. Bottom line — a concise reconciliation of the claims and the evidence

The core claim that human ivermectin tablets commonly contain microcrystalline cellulose, pregelatinized starch, and magnesium stearate is supported across multiple package inserts and product monographs in the dataset, while additional excipients like croscarmellose sodium, colloidal silicon dioxide, BHA, and citric acid appear variably depending on brand and document date ^{[1] [2] [4]}. For precise guidance, stakeholders should reference the specific product insert for the batch or brand in question because minor but clinically relevant excipient differences exist; the provided sources collectively document both the consensus ingredients and the brand-level deviations that inform that recommendation ^{[1] [2] [3] [4]}.